Replies to post #365 on Sunshine Biopharma Inc (SBFM)

[Kooka_Duke]

""Mega Due Diligence On SBFM""

**What We Have Here Players Is a Super Low Floater That Moves On Vapor**......Earlier This Year SBFM Was Trading In Dollarland.....With Good Solid News On Its Phase 1 Update This Sweet Thang Can Get Back There In a Heartbeat!




Overview Of Sunshine Biopharma Inc.

According to the American Cancer Society:

•Approximately 1.5 million new cases of cancer are diagnosed each year in the U.S.
•Over 11 million Americans are living with cancer.
•Virtually all cancers are either aggressive at the onset or become aggressive over time.
•The overall cost of disease treatment is over $126 billion annually.

Aggressive Cancers

•There are two genes which are associated with aggressive forms of cancer: Her2 and Top2
•Herceptin (R)* is an effective treatment for Her2 positive patients.
•There are currently no effective therapies that target Top 2.
•*Herceptin (R)* sales are $1.8 Billion per year.


The Her2 and Top2 Genes

•Her2 gene encodes Human Epidermal Growth Factor Receptor 2
•Top 2 gene encodes Topoisomerase II, an enzyme that unwinds DNA and is required for cell proliferation.
•Her2 and Top2 are located on Chromosome 17 near the BRCA1 gene at 17q21-q22.
•Top2 is often co-amplified in aggressive cancers.
•As many as 10 copies of the Top2 gene have been found in Multi-Drug Resistant Breast Cancer cells.


Inhibition of the Top2 Enzyme

•Inhibition of Topoisomerase II activity (Top2) is essential in the fight against aggressive types of cancer, including multi-resistant breast cancer.

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

""Real Product..,Real Company Patents Pending Players""

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

""<<Recent News Players>>""

""SUNSHINE BIOPHARMA AND BINGHAMTON UNIVERSITY (STATE UNIVERSITY OF NEW YORK) ENTER INTO RESEARCH AGREEMENT"".....

Sunshine Biopharma, Inc. (OTCBB Ticker Symbol: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).


As a result, the parties will begin conducting the necessary research and development to advance Sunshine's lead compound, Adva-27a through various stages of preclinical development and Phase I clinical trials for breast cancer and prostate cancer.

(""Mega News Players Phase 1"")

The Agreement shall be in force for a period of three (3) years from the Effective Date and shall be renewed automatically for additional one (1) year periods until the Project is completed, unless the research is completed prior to the initial three year term of the Agreement. Adva-27a is a small molecule that inhibits Topoisomerase II, an enzyme found in abundance in Multi-Drug Resistant breast cancer as well as in other types of aggressive cancer.

Dr. Steve Slilaty, Sunshine's President and CEO, stated "we are very excited to sign the agreement with Binghamton University. This is the next step for us and we believe Adva-27a is a much more effective inhibitor of Topoisomerase II without the risks of toxicity or significant adverse side effects. Data published in our issued and pending patent applications have shown that Adva-27a is three times more effective in arresting cancer cell growth than its current market competitor."(That Would Be The GIANT Pharma Company Roche)

Dr. Slilaty also stated "We anticipate completion by the first half of 2012 and if things go as we expect, we anticipate Adva-27a to be available for "compassionate-use" by the end of the trial. We are excited by the challenges ahead and the potential to make a difference in the length and quality of life for many cancer patients throughout the world".

.....

Confirmation Of These Binding Agreement Here>>>>>

Dr. Susannah Gal, Associate Professor in the Department of Biological Sciences at Binghamton University, stated "I look forward to pursuing laboratory studies and coordinating clinical trials to better understand the action of this exciting new drug. If these studies pan out as expected, this drug could have a dramatic positive impact in the clinic. As a cancer survivor myself, it is gratifying to potentially help those facing the ravages of this disease with our work on this compound."

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

""Sunshine Biopharma Looking to Mimic Roche's Billion Dollar Cancer Drug Success....

Sunshine Biopharma, Inc. (OTCBB: SBFM)


Sunshine is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date. The company's flagship compound in development is Adva-27, a small molecule that targets and inhibits Topoisomerase II (Top2), an enzyme found in abundance in various types of aggressive carcinomas.

It is widely-known that there are two genes which are associated with aggressive forms of cancer: Her2 (human epidermal growth factor receptor-2) and Top2. Swiss drug maker Roche's Herceptin® (Trastuzumab) is an effective treatment for Her2 positive patients. Showcasing the magnitude of usage for a viable indication addressing one of the genes, Herceptin® generated roughly $7 billion in global sales for Roche in 2010.....""If SBFM Can Capture 30% Of This Market That Would Be 2.1B!......That's a ""Bigg Number Players""

Recently, Sunshine announced that it has completed a detailed cytotoxicity study, a measure of a drug's ability to destroy cancer cells in vitro, of Adva-27a, in MCF-7/MDR, a multidrug resistant breast cancer cell line. According to the Company, the study's results showed that Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells than Etoposide, a current commonly used drug. In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs. Multi-drug resistance is a major component in the failure of many of today's chemotherapies, so drugs that show the ability to thwart the resistance factor are heralded as particularly valuable from both a humanitarian and financial standpoint.

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

The life span of a biotech stock play runs in cycles with one area of common upward price movement being the commencement of clinical trials. Sunshine is nearing that milestone with McGill University's The Jewish General Hospital already agreeing to host the Phase I clinical trials.

A thinly traded stock with a paltry market cap of under $30 million, biotech investors will be on the lookout for news of the human trials and any further cancer drug development news that could be the catalyst required to drive the share value to the next level.

Sunshine Biopharma Aims to Follow in Herceptin's Footsteps

Sunshine Biopharma Inc. (OTCBB:SBFM) - Aggressive breast cancer has been traced to two key genetic culprits: the HER2 and TOP2 genes. Roche's Herceptin drug is the standard of care for HER2 positive patients, but there is currently no therapy that targets TOP2.

Enter Sunshine Biopharma (OTCBB:SBFM) of Montreal.

Its flagship compound, Adva-27a, has shown "phenomenal results" in early testing to target and inhibit the Topoisomerase 2 (Top2) enzyme, one of the most important targets for treating aggressive cancer, CFO Camille Sebaaly says in an exclusive interview with BioTuesdays.com.

Read The Entire Interview Here Players!

"Our technology is unique," he says, adding that Sunshine is the "only company that has a Top2 inhibitor" and that "we have two patents covering our technology and lead compound."

Investor interest in Sunshine exploded last month after the company disclosed that it had completed a detailed cytotoxicity study (a measure of a drug's ability to destroy cancer cells in vitro) of Adva-27a in a multidrug resistant breast cancer cell line.

The study's results showed that Adva-27a is 16 times more effective at killing multidrug resistant breast cancer cells than Etoposide, the current chemotherapy of choice.

In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery which makes cancer cells resistant to drugs, a major reason for the failure of many chemotherapies.

Mr. Sebaaly says that when aggressive cancer cells make too much of the Top2 enzyme, cells proliferate and metastasize. He states, "So, if you can inhibit or destroy the activity of Top2, you would then be able to prevent cancer cells from spreading." Moreover, the more Top2 the cell makes, the more effective Adva-27a is at killing that cell, he adds.

SBFM Is Very Undervalued Here @ .48 Players!

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++


SS:
A/S 50M
O/S 30,711,342
Float 12.9M

[pennystockguru2011]

It's only a matter of time...